<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779428</url>
  </required_header>
  <id_info>
    <org_study_id>CA200-002</org_study_id>
    <nct_id>NCT00779428</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin</brief_title>
  <official_title>Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to provide treatment to patients who have participated&#xD;
      on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>There is no Primary Outcome</measure>
    <time_frame>No formal analysis of efficacy will occur</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanespimycin</intervention_name>
    <description>Solution, IV&#xD;
This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)</description>
    <arm_group_label>A1</arm_group_label>
    <other_name>BMS-722782</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Participated in and completed a previous Tanespimycin protocol without evidence of&#xD;
             unacceptable toxicity and is deemed by the Investigator to be deriving benefit from&#xD;
             the Tanespimycin drug as defined in the previous protocol&#xD;
&#xD;
          -  All patients must rollover to this continuation protocol within 30 days of the last&#xD;
             dose of Tanespimycin in the previous protocol, unless previously approved by the&#xD;
             Medical Monitor&#xD;
&#xD;
          -  All Adverse Events from the prior protocol, must have resolved to NCI CTCAE (v. 3.0)&#xD;
             Grade &lt;= 2&#xD;
&#xD;
          -  The following laboratory results, within 10 days of Tanespimycin administration:&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dL&#xD;
&#xD;
          -  Absolute neutrophils count &gt;= 1.0x 10*9* /L&#xD;
&#xD;
          -  Platelet count &gt;= 50 x 10*9* /L&#xD;
&#xD;
          -  Serum bilirubin &lt;= 2 x ULN&#xD;
&#xD;
          -  AST &lt;= 2.5 ULN&#xD;
&#xD;
          -  Serum creatinine &lt;= 2 x ULN&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing neuropathy of CTCAE Grade &gt;= 3 due to any cause&#xD;
&#xD;
          -  Documented hypersensitivity reaction of CTCAE Grade &gt;= 3 to prior therapy containing&#xD;
             Cremophor (for those patients receiving Tanespimycin Injection)&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Administration of chemotherapy, biological, immunotherapy or investigational agent&#xD;
             (therapeutic or diagnostic), excluding Tanespimycin within 21 days prior to receipt of&#xD;
             study medication&#xD;
&#xD;
          -  Any medical conditions that, in the Investigator's opinion, would impose excessive&#xD;
             risk to the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>This is an open-label continuing treatment protocol in patients with advanced malignancies who will receive Tanespimycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

